Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL7259752 | 0.98 | LMNA (0.57) | LMNATHRBALDH1A1MAPK1TDP1 | |
| Butane SCHEMBL1088110 | 0.95 | LMNA (0.55) | LMNATHRBALDH1A1 | |
| Acetonitrile SCHEMBL7254198 | 0.89 | LMNA (0.48) | LMNA | |
| Propionaldehyde SCHEMBL1523503 | 0.84 | LMNA (0.67) | LMNATHRBALDH1A1MAPK1TDP1 | |
| Formic Acid SCHEMBL6366884 | 0.84 | LMNA (0.67) | LMNATHRB | |
| SCHEMBL10762210 | 0.84 | LMNA (0.52) | LMNATHRBALDH1A1 | |
| Propylene Glycol SCHEMBL9621813 | 0.82 | LMNA (0.50) | LMNAALDH1A1MAPK1TDP1 | |
| Malonaldehyde SCHEMBL6704192 | 0.82 | LMNA (0.63) | LMNATHRBALDH1A1MAPK1TDP1 | |
| SCHEMBL11485155 | 0.82 | LMNA (0.63) | LMNATHRBALDH1A1MAPK1TDP1 | |
| SCHEMBL4293299 | 0.81 | LMNA (0.71) | LMNATHRBALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119114033-A | Low-protein-adsorptivity blood perfusion adsorbent, preparation method thereof and blood perfusion device | 泉州师范学院 | 2024-12-13 | — | — | CN | claimed |
| US-8969632-B2 | Passivation of a homogeneous hydrogenation catalyst for the production of ethylene glycol | EASTMAN CHEMICAL COMPANY (US) | 2015-03-03 | — | — | US | claimed |
| EP-2828229-A1 | PASSIVATION OF A HOMEGENEOUS HYDROGENATION CATALYST FOR THE PRODUCTION OF ETHYLENE GLYCOL | Eastman Chemical Company (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142091-A1 | PASSIVATION OF A HOMEGENEOUS HYDROGENATION CATALYST FOR THE PRODUCTION OF ETHYLENE GLYCOL | EASTMAN CHEMICAL COMPANY (US) | 2013-09-26 | — | — | WO | claimed |
| US-20130253230-A1 | PASSIVATION OF A HOMOGENEOUS HYDROGENATION CATALYST FOR THE PRODUCTION OF ETHYLENE GLYCOL | EASTMAN CHEMICAL COMPANY (US) | 2013-09-26 | — | — | US | claimed |
| US-8497337-B2 | Process for producing water-absorbing polymer particles with improved color stability | BASF SE (DE) | 2013-07-30 | — | — | US | claimed |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2012-05-31 | — | — | US | claimed |
| EP-2419421-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | Sandoz AG (CH) | 2012-02-22 | — | — | EP | claimed |
| WO-2010118992-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | SANDOZ AG (CH) | 2010-10-21 | — | — | WO | claimed |
| CN-119114033-A | Low-protein-adsorptivity blood perfusion adsorbent, preparation method thereof and blood perfusion device | 泉州师范学院 | 2024-12-13 | — | — | CN | disclosed |
| CN-113699195-A | Method for biosynthesis of xylose | 中国科学院天津工业生物技术研究所 | 2021-11-26 | — | — | CN | disclosed |
| CN-108101881-B | Process for the preparation of trabectedin and intermediates thereof | 江苏恒瑞医药股份有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-111683922-A | Process for producing alpha-hydroxy compound and use thereof | 托普索公司 | 2020-09-18 | — | — | CN | disclosed |
| US-8969632-B2 | Passivation of a homogeneous hydrogenation catalyst for the production of ethylene glycol | EASTMAN CHEMICAL COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| WO-1994000149-A1 | ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR $i(HAEMOPHILUS INFLUENZAE) | MICROCARB INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0565590-A1 | ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR $i(HAEMOPHILUS INFLUENZAE) | MicroCarb Inc. (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992010936-A1 | ADHESIN-OLIGOSACCHARIDE CONJUGATE VACCINE FOR $i(HAEMOPHILUS INFLUENZAE) | MICROCARB, INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| US-4864023-A | MICROBIOCIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4801584-A | ANTIMICROBIAL | HOFFMANN-LA ROCHE INC. (US) | 1989-01-31 | — | — | US | disclosed |
| US-4405821-A | REACTING FORMALDEHYDE, CARBON MONOXIDE, AND HYDROGEN WITH RHODIUM AND PHOSPHINE OXIDE CATALYSTS TO FORM GLYCOLALDEHYDE, THEN CATALYTIIC HYDROGENATION TO YIELD ETHYLENE GLYCOL | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253230-A1 | PASSIVATION OF A HOMOGENEOUS HYDROGENATION CATALYST FOR THE PRODUCTION OF ETHYLENE GLYCOL | HPD, TALDO1, GRHPR | LMNA 4660/4885THRB 2817/4885ALDH1A1 688/4885 |
| US-20120136015-A1 | PROCESS FOR PREPARATION OF ENDOTHELIAL RECEPTOR ANTAGONIST (BOSENTAN) | EDNRA, EDNRB, TBXA2R | LMNA 1696/4885THRB 781/4885ALDH1A1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.